Compare AI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | TRVI |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2020 | 2019 |
| Metric | AI | TRVI |
|---|---|---|
| Price | $11.07 | $13.30 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $8.90 | ★ $28.18 |
| AVG Volume (30 Days) | ★ 3.8M | 1.5M |
| Earning Date | 12-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $250,268,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.68 | $9.82 |
| 52 Week High | $16.40 | $20.22 |
| Indicator | AI | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 46.21 |
| Support Level | $11.07 | $13.00 |
| Resistance Level | $11.14 | $13.55 |
| Average True Range (ATR) | 0.54 | 0.88 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 0.33 | 21.47 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions, namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications; C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications; and C3 Generative AI, which combines the utility of large language models. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.